Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity
Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity: A Randomized, Comparative Study
National Cancer Institute, Egypt
58 participants
Oct 20, 2025
INTERVENTIONAL
Conditions
Summary
The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.
Eligibility
Inclusion Criteria6
- Age from 18 to 60 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status of II-III.
- Height between 150-185 cm.
- Body mass index between 18-35 kg/m².
- Scheduled for above-knee amputation due to lower limb sarcomas.
Exclusion Criteria5
- Allergy to any of the investigated drugs.
- History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.
- Contraindications to spinal anesthesia.
- Pregnancy or lactation.
- Presence of psychiatric illness or chronic pain conditions.
Interventions
Patients will receive 2.5 mL of 0.5% hyperbaric bupivacaine with 25 µg fentanyl + 5 µg dexmedetomidine.
Patients will receive 2.5 mL of 0.5% hyperbaric bupivacaine with 25 µg fentanyl.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07276867